OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]
January 10, 2021Read More
US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 (synthetic hypericin) in cutaneous T-cell lymphoma (CTCL). The late-stage study enrolled 169 subjects in the FLASH clinical trial. This was after Soligenix secured positive interim analysis, which included a prospectively […]
Continue reading …
Researchers in the US have developed a new skin patch as a potentially new melanoma treatment by delivering medication to cancer cells in one minute. Microneedle patch, which could be used to deliver vaccines to combat different infectious diseases, was tested in mice and human skin samples. Melanoma, a form of skin cancer, has been […]
Continue reading …
Novartis has secured approval from the European Commission (EC) for its skin cancer drug combo Tafinlar (dabrafenib) and Mekinist (trametinib) as an adjuvant therapy for stage III patients with BRAF V600 mutation-positive melanoma after complete surgical resection. The latest approval marks the third for the Tafinlar-Mekinist combination in Europe for various tumor types identified with […]
Continue reading …